Eli Lilly (NYSE:LLY) released positive Phase 2 results for its small interfering RNA (siRNA) drug candidate lepodisiran on Sunday. The trial results showed 94% lower levels of a genetically inherited ...

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that inhibits the body's production of a dangerous type of "bad" cholesterol." ...

Lepodisiran, a new drug, slashed levels of “stealthy cholesterol”—a hidden heart risk affecting 1 in 5 people—by up to 95% in ...

New drug shows impressive results against lipoprotein(a), a genetic form of cholesterol that affects millions but remains ...

Researchers have discovered an experimental medication that significantly reduces a cholesterol-like particle that can ...

Eli Lilly (NYSE:LLY) has recently announced several developments, including positive Phase 2 results for their siRNA therapy ...

Eli Lilly has reported promising Phase II results for lepodisiran, its experimental therapy aimed at reducing lipoprotein(a) [Lp(a)], a genetically inherited risk factor for heart disease.

Eli Lilly (LLY) and Company announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA, siRNA, therapy designed to lower the production of lipoprotein ...

A single dose of an siRNA molecule reduces elevated lipoprotein(a) — a major, but to date, largely untreatable risk factor ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Eli Lilly (NYSE:LLY) released positive Phase 2 results for its small interfering RNA (siRNA) drug candidate lepodisiran on Sunday. The trial results showed 94% lower levels of a genetically ...